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Summary The CYFRA 21-1 assay is a test that has been developed recently for detection of a cytokeratin 19
fragment in serum. A diagnostic role for CYFRA 21-1 has already been proposed. The question of whether
this marker is prognostically significant is important in clarifying the role of CYFRA 21-1 in clinical practice.
The aim of this study was to evaluate the prognostic significance of elevated preoperative CYFRA 21-1 levels
in patients with resected primary squamous-cell lung cancer (SqCC). Serum levels of CYFRA 21-1 were
measured using an immunoradiometric assay (CIS bio) in 91 patients with operable SqCC. Survival and
disease-free survival curves related to initial levels of this marker were estimated using the Kaplan-Meier
method. In the univariate analysis the log-rank test and the log-rank test for trend were used. In the
multivariate analysis the stratified log-rank test and the proportional hazard model were used. Elevated
preoperative CYFRA 21-1 levels were identified in 55% of patients with SqCC. The number of patients with
elevated levels of this marker increased with TNM stage (P=0.0001). In univariate analysis elevated levels of
CYFRA 21-1 were significantly associated with poor overall survival (P<0.00005) and with disease-free
survival (P<0.00005). In multivariate analysis elevated levels of this marker were also found to be associated
with poor overall and disease-free survival (P=0.01 and P=0.003 respectively). In conclusion, CYFRA 21-1
may be an independent prognostic parameter of survival and tumour relapse in SqCC and may be useful in
identifying resected SqCC patients at high risk of treatment failure.
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Squamous-cell lung carcinoma comprises 40-50% of all
cases of lung cancer. Its treatment is primarily surgical and
its prognosis has remained almost unchanged over recent
years. As is the case with other neoplasma, it would appear
valuable to segregate patients with squamous cell lung
carcinoma into different prognostic categories at the time of
diagnosis because this approach may assist in the selection of
types of treatment. Today, for patients with lung carcinoma,
the TNM staging system is the most important prognostic
factor. However, the variability of survival within staging
groups required additional types of indicators, independent
of stage to generate a 'comprehensive' estimate of prognosis
(Fielding et al., 1992).
Recently, great attention has been focused on the biology
of lung cancer and a number of so-called tumour markers
have been described (Richardson and Johnson, 1993;
Buccheri and Ferigno, 1994; Mountain, 1995; Niklinski and
Furman, 1995). One group of molecules that has been shown
to be promising as tumour markers is the cytokeratins (Moll
et al., 1982).
Cytokeratins are one of the main families of intermediate
filaments which make up the cytoskeleton. A cytokeratin is a
heterotypic tetramer of protofilaments composed of two
polypeptides: one acidic type I subunit and one basic type II
subunit (Nagle, 1988). It is noteworthy that each type of
epithelia and its malignant counterpart expresses a specific
cytokeratin pattern. Immunohistochemical studies have
demonstrated that simple epithelia, including respiratory
epithelia, express cytokeratins 7, 8, 18 and 19 (Moll et al.,
1990). These cytokeratins, and particularly CK 19, are
strongly expressed by lung cancer tissue (Broers et al.,
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1988). Although cytokeratins are part of the cytoskeleton,
some fragments might be released in the serum owing to cell
lysis or tumour necrosis.
A new tumour marker assay (CYFRA 21-1) which uses
two monoclonal antibodies (KS 19-1 and BM 19-21) against
epitopes of a water-soluble fragment of CK 19, was recently
introduced (Pujol et al., 1993; Bodenmuler et al., 1994).
The results of initial studies of CYFRA 21-1 in lung
cancer patients showed its dominant value in squamous-cell
carcinoma type (Pujol et al., 1993; Stieber et al., 1993;
Bombardieri et al., 1994; Rastel et al., 1994; Rapellino et al.,
1995). The current study examines whether elevated serum
CYFRA 21-1 levels have any prognostic value in patients
with resected squamous-cell lung cancer.
Material and methods
The study includes 91 squamous-cell lung cancer (SqCC)
patients examined by the Chest Oncology Group and
operated on in the Thoracic Surgery Unit at the Bialystok
Medical School between May 1991 and June 1993. All of
these patients underwent surgical resection. No patient
underwent chemotherapy or radiation therapy before surgery.
Pretreatment staging procedures included physical and
blood examinations, chest radiographs and tomographs,
bronchoscopy, computed tomography (CT) of the thorax
and ultrasound scanning of liver. In addition, radioisotopic
scans of bones, examination of bone marrow aspirates and
abdominal and brain CT scans were performed when
necessary. Selected patients underwent mediastinoscopy. All
patients were of good performance status at the time of
surgery (Karnofsky, 80 to 100). During operation, radical
lymph node dissection was uniformly performed. Nodes were
identified and submitted separately at all levels. Pathological
material has been specially reviewed for this study by the
same pathologist. Post-operative, pathological staging
(pTNM) (primary tumour, regional lymph involvement,occurrence of distant metastasis) was performed by correlat-
ing the operative and histological findings (Mountain, 1986).
After surgery, patients were followed at 3 month intervals
with a clinical and radiological examination.
At the time of our analysis, 30 patients had died. Two
patients (2%) died of complications after surgery (operative
death) and three patients died 33, 34 and 36 months after
surgery, respectively, due to an unrelated cause. In these three
cases, no tumour recurrence had been detected. A total of 25
remaining patients had died owing to recurrence of the
disease. Three patients with recurrence are alive at 3 months
after the second treatment (one patient was able to undergo a
second resection, the other two were treated with radiation
therapy).
In the whole group of patients (excluding the two patients
who died of complications after surgery) the length of follow-
up ranged from 11 to 38 months. In the group of 62
surviving patients, follow-up ranged from 11 to 36 months;
35 of those patients (57.4%) were observed for 36 months
after surgery.
To determinate CYFRA 21-1 serum levels, venous blood
samples were collected from each patient before surgery,
centrifuged to obtain serum samples and stored at -80°C
until assayed. All samples were assayed in duplicate. Serum
levels of CYFRA 21-1 were measured with immunoradio-
metric assay, using a commercial source (CIS bio interna-
tional, Gif/Yvette, France), following the manufacturer's
instructions. The cut-off point was 3.6 ng ml-'.
Statistical analysis
Comparisons based on contingency tables were performed
using the Fisher's exact test and the exact test for trend
(Agresti, 1990). Survival time was calculated from the time of
surgery to the date of death or the last observation of a
patient. Patients alive at the end of the follow-up were
regarded as censored observations. Disease-free survival time
was calculated from the date of surgery to the date of the first
occurrence of relapse or death or to the date of the last
observation of a patient. Patients alive and free of disease at
the end of the follow-up were regarded as censored
observations.
Overall survival and disease-free survival curves related to
initial serum CYFRA 21-1 level were estimated using the
Kaplan-Meier method. Confidence intervals (95%) for the
estimated probability of overall and disease-free survival were
calculated using the asymptotic variance of the log-log
transformation of the survivor function (Kalbfleisch and
Prentice, 1980).
In the univariate analysis of the log-rank test (exact and
asymptotic version) and the log-rank test for trend
(asymptotic version; Tarone and Ware, 1977) were used. In
the multivariate analysis the (exact) stratified log-rank test
and proportional hazard model were used. Comparisons
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based on multivariate models were performed using the score
test. The fit of models was checked both graphically and
using time-dependent covariates (Kalbfleisch and Prentice,
1980).
All the tests performed in the univariate and the
multivariate analyses were two-sided. The exact tests were
computed using StatXact-Turbo v.2.0 software. Confidence
intervals for the estimated probability of overall and disease-
free survival were calculated using Stata v.3.0. The other
methods were applied using BMDP/dynamic v.7.0 (programs
11 and 21).
Results
At the time of diagnosis 55% (50/91) of SqCC patients had
CYFRA 21-1 levels higher than 3.6 ng ml-'. Concentration
of serum CYFRA 21-1 according to patients' characteristics
is shown in Table I.
CYFRA 21-1 values differ significantly among groups
defined by the TNM classification and age. When compared
at 0.01 significance level (adjusted for the fact of performing
multiple comparisons), it appears that the number of patients
with elevated CYFRA 21-1 levels increases with TNM stage
(P=0.0001), decreases with age (P<0.00005) and does not
depend on sex (mid-P=0.86). Thus, there is a significant
imbalance between the group of patients with a normal and
an elevated CYFRA 21-1 level with respect to the
distribution of TNM and age, which has to be taken into
account in the analysis.
Overall survival analysis
In the analysis 91 patients were included. In this group of
patients 30 deaths were observed. Four factors were
investigated for their influence on the survival of the
patients: sex, age (<50, 50-64, 65 years), TNM stage (I,
II, lIla) and the level of CYFRA 21-1 (normal, <3.6;
elevated, > 3.6 ng ml-').
The univariate analysis was based on the results of the log-
rank test. Taking into account the fact that multiple
comparisons were made, the 0.01 level of significance was
adopted. The results of the test for age (P<0.00005), TNM
(P=0.005) and CYFRA 21.1 level (P<0.00005) were found
to be significant (Table II). The presence of an elevated level
of CYFRA 21-1 was associated with a shorter survival time
of patients (Figure 1).
In the multivariate analysis the (exact) stratified log-rank
test for the level of CYFRA 21-1 factor, with strata defined
by different combinations of age and TNM stage, was used
first. The result (P=0.02) was significant at the 0.05 level
(Table II). Secondly, an analysis using the proportional
hazard model was performed. It was found that a stratified
model (Table III), with two strata defined by TNM stage (I
Table I CYFRA21-1 serum levels categorised by patients' characteristics
Quartiles
Mean Median 25% 75% No. of cases
(ngmrl) (ngml') (ngmr') (>3.6ngml-) P-value
TNM 0.OOOla
I 2.47 2.15 0.975 3.90 6/22 (27%)
II 3.75 3.40 2.05 5.20 18/37 (49%)
Illa 9.10 9.70 5.90 11.875 26/32 (81%)
Sex 0.86b
M 5.35 4.20 2.10 7.40 46/83 (55%)
F 5.06 3.75 2.175 9.15 4/8 (50%)
Age <0.0OOOSa
<50 7.53 6.70 3.90 11.90 12/15 (80%)
50-64 6.38 5.40 3.55 7.675 34/46 (74%)
>64 2.60 2.00 1.00 2.50 4/30 (13%)
aExact test fortrend; bmid P-value for the Fisher's exact test.CYFRA 21-1 in squamous cell lung cancer
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Table II Overall survival-the results of the univariate analysis
Estimatedprobability of
No. ofdeathsl surviving >2.5 years
no. ofpatients (with 95% CI) P-value
CYFRA 21- <0.00005a (0.02)b
<3.6ngml 1 1/41 1.00OC
>3.6ngml-1 29/50 0.501 (0.346-0.638)
TNM 0.005d
I 4/22 0.889 (0.623-0.971)
II 8/37 0.811 (0.603-0.917)
lIla 18/32 0.471 (0.281-0.640)
Age (years) <0.00005d
<50 10/15 0.429 (0.177-0.661)
50-64 19/46 0.593 (0.407-0.738)
>64 1/30 1.00OC
Sex 0.18a
M 26/83 0.718 (0.592-0.810)
F 4/8 0.343 (0.117-0.814)
aExact log-rank test; bexact stratified log-rank test (adjusted for the TNM and age); Cconfidence interval
cannot be calculated; dlog-rank test for trend based on the asymptotic distribution.
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Figure 1 Probability of survival of patients with normal and
elevated preoperative CYFRA 21-1 level.
and II vs Illa), gave the closest fit to the data. The score test
for the null hypothesis that all the effects of the covariates
included in the model are zero resulted in a P-value equal to
0.0001. The effect of an elevated CYFRA 21-1 level was
found to be significant at the 0.05 significance level (P =0.01),
with a relative risk estimate of 15.91.
Disease-free survival analysis
In the group of 91 patients analysed, 28 recurrences and five
deaths without recurrence were observed. Of 28 patients who
relapsed, 25 died after a recurrence and three were alive after
a second treatment. The same factors as in the overall
survival analysis were considered.
In the univariate analysis (Table IV) the results of the log-
rank tests for age (P<0.00005), TNM (P=0.003) and
CYFRA 21-1 level (P<0.00005) were significant at the 0.01
significance level (adjusted for the multiple comparisons). The
presence of an elevated level of CYFRA 21-1 was associated
with a shorter disease-free survival time (Figure 2). The
approach to the multivariate analysis was similar to the one
chosen in the overall survival case. In the first step, the
(exact) stratified log-rank test for CYFRA 21-1 level, with
strata defined by different combinations ofthe age and TNM,
was performed. It resulted in P=0.003, which was significant
at the 0.05 significance level.
In an attempt to use the proportional hazard model it was
found that there was a need to use a model stratified by age.
Table III Overall survival-proportional hazard model (stratified
for TNM stage I and II vs IIIa)
RR 95% CIfor RR P-valuea
CYFRA 21 -1
<3.6ngml-1 1
>3.6ngml 1 15.91 (1.51-167.2) 0.01
Age (years) 0.48b (0.23C)
<50 1
50-64 0.66 (0.28-1.56) 0.34
>64 0.32 (0.03-3.51) 0.34
Sex
F 1
M 0.44 (0.68-1.47) 0.17
aFor the score test; boverall P-value for the effect ofage; cP-value
for trend; the test was obtained by replacing by a linear covariate the
two indicator variables for the age groups; the replacement does not
introduce any qualitative changes to the conclusions based on the
model presented in the table.
However, fitting a model stratified by age with CYFRA 21-1
level as a covariate was impossible because the likelihood
function appeared to be monotone in the coefficient related to
the covariate (Bryson and Johnson, 1981). This was due to
the fact that among younger patients (<64 years) recurrences
and deaths without recurrence were observed only for those
having elevated levels of CYFRA 21-1, while among the
oldest patients (>64 years) there were no recurrences and
only one death was observed (for a patient with normal
CYFRA 21-1 level). Since it was impossible to fit a model
stratified by age, which would contain CYFRA 21-1 as a
covariate, it was decided to limit the multivariate analysis of
the disease-free survival to the use of the stratified log-rank
test.
Discussion
The conventional approach to assessing prognosis in patients
with lung cancer has been to place great importance on stage
of disease and anatomical and pathological variables, such as
tumour size, histological subtype and degree of tumour
differentiation. Recent advances in the understanding of lung
tumour biology provide insights into many other potentially
significant determinants of prognosis.
The possibility that long-term results or response to
treatment are based on biological factors inherent in the
tumour cells has been confirmed (Fielding et al., 1992;CYFRA 21-1 in squamous cell lung cancer
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Table IV Disease-free survival-results of the univariate (log-rank test) and multivariate (stratified log-rank test) analysis
No. ofpatients alive No. ofpatients alive Estimated probability
after relapse/No. without relapsel ofsurviving without
of deaths after No. ofdeaths relapse >2.5 years
relapse without relapse (with 95% CI) P-value
CYFRA 21 -1 <0.00005a
(0.003)b
<3.6 0/0 40/1 1.OOOC
>3.6 3/25 18/4 0.455 (0.304-0.595)
TNM 0.003d
I 0/3 18/1 0.839 (0.579-0.945)
II 1/6 28/2 0.773 (0.561-0.891)
Illa 2/16 12/2 0.463 (0.271 -0.634)
Age (years) <0.00005d
<50 2/9 3/1 0.429 (0.177-0.660)
50-64 1/16 26/3 0.541 (0.360-0.692)
>64 0/0 29/1 1.OOOC
Sex 0.13a
M 3/21 54/5 0.698 (0.570-0.794)
F 0/4 4/0 0.365 (0.053-0.706)
aExact log-rank test; bexact stratified log-rank test (adjusted for age and TNM); cconfidence interval cannot becalculated; dlog-
rank test for trend based on the asymptotic distribution.
100 .1 - CYFRA 21-1 was associated with a shorter failure time. For
the overall and disease-free survival the negative effect of an
elevated level of this marker was found to be statistically
significant both in the univariate and multivariate analyses.
Interestingly, in the group of 50 patients with an elevated
CYFRA 21-1 level there were 29 deaths, while in the group
50 =l-, of 41 patients with normal CYFRA 21-1 level only one death
was observed. Among 50 patients with elevated CYFRA 21-1
level there were 28 recurrences, while in the group of 41
25 patients with a normal level of this marker no recurrences
s-CYFRA 3.6 ng m1- -L were observed. Additionally, among younger patients (,<64
-- s-CYFRA> 3.6 ng mlF years) recurrences were observed only for those having
0 X I I I I elevated levels of CYFRA 21-1. These results suggest that
0 6 12 18 24 30 36 42 the CYFRA 21-1 assay may be applicable to patients of a
Months younger age group.
Others (Pujol et al., 1993) found that CYFRA 21-1 was
re 2 Probability of disease-free survival of patients with also an independent prognostic factor in their entire
ial and elevated preoperative CYFRA 21-1 level. population of lung cancer (NSCLC and SCLC) along with
performance status and disease stage.
Recently we reported the significant role of CYFRA 21-1
in post-operative monitoring of patients for the detection of
iski and Furman, 1995). Additionally it has been tumour recurrence (Niklinski et al., 1995). Curative surgery
sted that the information that describes anatomical resulted in a significant drop of preoperatively elevated
of tumour and additional types of prognostic marker CYFRA 21-1 levels down to normal values, whereas steadily
I be combined increasing marker concentrations predict or accompany
nsiderable interest has been focused on a new clinical relapse.
irker-soluble fragment of cytokeratine 19 'CYFRA 21- Promising results have also been obtained in the
e now confirm that CYFRA 21-1 is a sensitive marker comparison of the clinical value of CYFRA 21-1 assays for
jCC and elevated levels of this marker were correlated disease monitoring with WHO response criteria with therapy
progression of tumour stage. In our previous study, we assessed using standard techniques (Gaast et al., 1994). It was
found a significant relationship between the elevated found that 84% of response evaluations yielded concordant
of CYFRA 21-1 and mediastinal lymph node results. More data, however, are needed to make sure
iement (Niklinski et al., 1994). whether the course of CYFRA 21-1 concentrations during
Ice the diagnostic role of CYFRA 21-1 has already been therapy reflects precisely the disease status. The present study
ited (Stieber et al., 1993; Ebert et al., 1995; Paone et al., suggests that the determination of CYFRA 21-1 may provide
Wieskopf et al., 1995), it is worthwhile investigating additional, independent, prognostic information in squa-
er pretreatment CYFRA 21-1 concentrations are mous-cell lung cancer patients.
related to the likelihood of relapse in lung cancer patients
who undergo curative resection.
In this paper we report results aimed at the evaluation of
CYFRA 21-1 as an independent prognostic factor to identify
squamous-cell carcinoma patients at high risk of surgical
treatment failure. We found that for the overall as well as
disease-free survival the presence of an elevated level of
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